APVO Company Profile and Key Details

Q: Who are the executives of APVO?

Dr. Dirk Huebner M.D.Chief Medical OfficerMs. SoYoung Kwon J.D., LL.M.Senior Vice President, Gen. Counsel, Bus. Devel. & Corporation AffairsDr. Jane A. Gross Ph.D.Chief Scientific OfficerMs. Daphne L. TaylorSenior Vice President & Chief Financial OfficerMr. Jeffrey G. Lamothe CAExecutive Vice President & Chief Operating OfficerMr. Marvin L. WhitePres, Chief Executive Officer & Director

NASDAQ : APVO

Aptevo Therapeutics

$0.59

-0.3427-36.85%

Open: 1:08 PM

58.64

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Aptevo Therapeutics Inc. (APVO) stock declined over -36.85%, trading at $0.59 on NASDAQ, down from the previous close of $0.93. The stock opened at $0.68, fluctuating between $0.50 and $0.69 in the recent session.

Stock Snapshot

0.9301

Prev. Close

17.37M

Market Cap

0.504

Day Low

N/A

P/E Ratio

1950.74

EPS (TTM)

-26.51

Cash Flow per Share

0.68

Open

16.85M

Number of Shares

0.69

Day High

99.2%

Free Float in %

27.62

Book Value

12.43M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Dec 24, 2025	1.02	1.04	0.91	0.93	910.2K
Dec 23, 2025	1.08	1.08	1.00	1.02	601.15K
Dec 22, 2025	1.07	1.11	1.06	1.10	462.41K
Dec 19, 2025	1.03	1.11	1.02	1.07	1.05M
Dec 17, 2025	1.10	1.10	1.02	1.03	556.09K
Dec 16, 2025	1.00	1.11	1.00	1.10	660.94K
Dec 15, 2025	1.09	1.09	1.00	1.04	897.29K
Dec 12, 2025	1.11	1.15	1.10	1.13	617.45K
Dec 11, 2025	1.14	1.16	1.07	1.16	1.22M
Dec 10, 2025	1.29	1.29	1.15	1.20	8.15M
Dec 09, 2025	1.30	1.33	1.15	1.24	1.99M
Dec 08, 2025	1.36	1.37	1.28	1.34	535.06K
Dec 05, 2025	1.39	1.39	1.34	1.35	478.42K
Dec 04, 2025	1.37	1.41	1.34	1.39	504.29K
Dec 03, 2025	1.28	1.38	1.26	1.38	312.93K
Dec 02, 2025	1.31	1.34	1.27	1.27	320.66K
Dec 01, 2025	1.36	1.42	1.30	1.32	492.12K
Nov 28, 2025	1.30	1.39	1.29	1.38	549.62K
Nov 26, 2025	1.23	1.29	1.21	1.28	458.96K
Nov 25, 2025	1.19	1.22	1.15	1.20	539.2K

Contact Details

Seattle, WA 98121

United States

https://www.aptevotherapeutics.com 206 838 0500

About Company

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Stock Peers

ARGX

4+0.47%

argenx SE$849.95 REGN

-1.46-0.19%

Regeneron Pharmaceuticals, Inc.$783.71 MDGL

0.61+0.10%

Madrigal Pharmaceuticals, Inc.$602.82 UTHR

4.2+0.82%

United Therapeutics Corporation$514.64 VRTX

3.78+0.82%

Vertex Pharmaceuticals Incorporated$462.99 ALNY

1.99+0.50%

Alnylam Pharmaceuticals, Inc.$400.69 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

-0.97-0.35%

Praxis Precision Medicines, Inc.$274.76 KRYS

-2.07-0.82%

Krystal Biotech, Inc.$251.29 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

Aptevo Therapeutics Inc. (NASDAQ:APVO) closed at $0.59 USD, losing -$0.34 (-36.85%) from the previous close of $0.93. The stock is currently mid-range between its 52-week high and low $0.50 and $109.80. With a market capitalization of about $17.37 million, Aptevo Therapeutics Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.42). Key stats such as the average daily volume over the past year has been around 2.09 million shares, trading with heavier-than-usual volume. Headquartered in Seattle, WA, Aptevo Therapeutics Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Marvin L. White, the company employs approximately 37 people and listed since July 20, 2016. Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States.

Technical Performance

APVO has shown weak momentum, losing -15.45% over the past week and -47.75% over the past quarter, though year-to-date performance is down -98.92%. Short-term trend indicators are bullishly aligned (SMA20 -21.74%, SMA50 -30.23%, SMA200 -87.08%). The stock’s 14-day RSI is 31.97 (weak momentum), while the ATR of 0.1 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -99.15% below its high and over -6.99% above its low. Average 10-day trading volume of 706.96 thousand shares is below the 3-month average of 1.84 million, indicating normal recent market interest.

Valuation Metrics

Aptevo Therapeutics Inc. trades at a P/E ratio of -0.03, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.11 suggesting the stock is closer to book value. The P/FCF stands at -1.12, also below market averages.

Dividend & Fair Value

Aptevo Therapeutics Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $14.79. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Aptevo Therapeutics Inc. generated EPS of -$185.07 over the past year. Five-year average earnings growth is 80.96%. Wall Street analysts project EPS growth of 90.39% annually over the next five years. The latest quarter delivered EPS of -$2.23. The next quarter is forecast at -$0.45. Next year's EPS is expected at $38.65. Aptevo Therapeutics Inc. earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by 6.7%. The prior quarter beat by -89.9%. Over the last six quarters, Apple has recorded several small beats. These include -13.47% in August 08, 2024.

Shareholding & Insider Activity

Aptevo Therapeutics Inc. has 16.85 million shares outstanding. The public float is 16.84 million shares, elevated short interest at 2.32% of float. This equals 391.02 thousand shares. The short ratio is 0.53 days. Institutional investors hold 2.95% of the float. Insiders own 0.08%. El-Hibri Fuad holds 1.12 million shares, White Marvin L has 293.60 thousand shares and Abdun-Nabi Daniel has 109.35 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Aptevo Therapeutics has not generated any revenue. Returns are negative, with ROA at -70.09% and ROE at -142.47%.
On valuation metrics, Aptevo Therapeutics trades at a P/E of -0.03, P/S of 0.00 and P/B of 0.11. The current ratio is 2.27 and quick ratio is 2.27. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -4508.91 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.65, supported by a cash flow-to-debt ratio of -5.86.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Aptevo Therapeutics posted revenue of $0.00, down slightly from $3.11M in the prior quarter. Gross profit was - $567.00K (margin 0.00%). Operating income was - $28.88M (margin 0.0%). Net income was- $17.41M (EPS - $62.62).
The company ended the quarter with $16.90M in cash and short-term investments, a total debt of $5.40M, and net debt of - $11.51M. Total assets were $24.84M, with equity of $12.22M. Financials further reflected weakness, with operating cash flow of - $11.73M, free cash flow of - $11.73M, and capital expenditures of $0.00.

Price Forecast & Outlook

Our AI price prediction model suggests that Aptevo Therapeutics Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -7.54%, with price expected at $0.86 by January 07, 2026, within a range of $0.74 to $0.99 3-Month Outlook: Projected fall of -92.47%, reaching $0.07 by March 24, 2026, with a range of $0.00 to $7.37. 1-Year Outlook: Projected loss of -98.92%, with price at $0.01 by December 24, 2026, within a range of $0.00 to $822.98.

Key Takeaways

Aptevo Therapeutics Inc. (NASDAQ:APVO) shares are down -98.92% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Aptevo Therapeutics Inc. trading at a premium to the broader market with a P/E of -0.03. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $7.00, suggesting 652.61% upside. Our AI forecast model points to short-term weakness (-7.54% over two weeks), a medium-term fall (-92.47% over three months), and a longer-term loss (-98.92% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Aptevo Therapeutics Inc. (APVO) stock price?

Aptevo Therapeutics Inc. (NASDAQ: APVO) stock price is $0.59 in the last trading session. During the trading session, APVO stock reached the peak price of $0.69 while $0.50 was the lowest point it dropped to. The percentage change in APVO stock occurred in the recent session was -36.85% while the dollar amount for the price change in APVO stock was - $0.34.

APVO's industry and sector of operation?

The NASDAQ listed APVO is part of Biotechnology industry that operates in the broader Healthcare sector. Aptevo Therapeutics Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of APVO?

Dr. Dirk Huebner M.D.
Chief Medical Officer
Ms. SoYoung Kwon J.D., LL.M.
Senior Vice President, Gen. Counsel, Bus. Devel. & Corporation Affairs
Dr. Jane A. Gross Ph.D.
Chief Scientific Officer
Ms. Daphne L. Taylor
Senior Vice President & Chief Financial Officer
Mr. Jeffrey G. Lamothe CA
Executive Vice President & Chief Operating Officer
Mr. Marvin L. White
Pres, Chief Executive Officer & Director

How APVO did perform over past 52-week?

APVO's closing price is 2.21% higher than its 52-week low of $0.50 where as its distance from 52-week high of $109.80 is -99.15%.

How many employees does APVO have?

Number of APVO employees currently stands at 37.

Link for APVO official website?

Official Website of APVO is: https://www.aptevotherapeutics.com

How do I contact APVO?

APVO could be contacted at phone 206 838 0500 and can also be accessed through its website. APVO operates from 2401 4th Avenue, Seattle, WA 98121, United States.

How many shares of APVO are traded daily?

APVO stock volume for the day was 12.43M shares. The average number of APVO shares traded daily for last 3 months was 2.09M.

What is the market cap of APVO currently?

The market value of APVO currently stands at $17.37M with its latest stock price at $0.59 and 16.85M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	37
Beta	1.42
Sales or Revenue	$0.00
5Y Sales Change%	-1%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

APVO Company Profile and Key Details

Aptevo Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Company Overview

Dividend & Fair Value

Valuation Metrics

Price Forecast & Outlook

Key Takeaways